Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 9 de 9
1.
Mol Psychiatry ; 26(3): 927-940, 2021 03.
Article En | MEDLINE | ID: mdl-31988435

Social memory processing requires functional CA2 neurons, however the specific mechanisms that regulate their activity are poorly understood. Here, we document that SorCS2, a member of the family of the Vps10 family of sorting receptors, is highly expressed in pyramidal neurons of CA2, as well as ventral CA1, a circuit implicated in social memory. SorCS2 specifically localizes to the postsynaptic density and endosomes within dendritic spines of CA2 neurons. We have discovered that SorCS2 is a selective regulator of NMDA receptor surface trafficking in hippocampal neurons, without altering AMPA receptor trafficking. In addition, SorCS2 regulates dendritic spine density in CA2 neurons where SorCS2 expression is enriched, but not in dorsal CA1 neurons, which normally express very low levels of this protein. To specifically test the role of SorCS2 in behavior, we generated a novel SorCS2-deficient mouse, and identify a significant social memory deficit, with no change in sociability, olfaction, anxiety, or several hippocampal-dependent behaviors. Mutations in sorCS2 have been associated with bipolar disease, schizophrenia, and attention deficient-hyperactivity disorder, and abnormalities in social memory are core components of these neuropsychiatric conditions. Thus, our findings provide a new mechanism for social memory formation, through regulating synaptic receptor trafficking in pyramidal neurons by SorCS2.


Memory , Nerve Tissue Proteins , Pyramidal Cells , Receptors, Cell Surface , Receptors, N-Methyl-D-Aspartate , Animals , Dendritic Spines/metabolism , Hippocampus/metabolism , Mice , Neurons/metabolism , Pyramidal Cells/metabolism , Receptors, N-Methyl-D-Aspartate/genetics , Receptors, N-Methyl-D-Aspartate/metabolism
2.
Am J Psychiatry ; 174(12): 1203-1213, 2017 12 01.
Article En | MEDLINE | ID: mdl-29084453

OBJECTIVE: Adolescence is a developmental stage in which the incidence of psychiatric disorders, such as anxiety disorders, peaks. Selective serotonin reuptake inhibitors (SSRIs) are the main class of agents used to treat anxiety disorders. However, the impact of SSRIs on the developing brain during adolescence remains unknown. The authors assessed the impact of developmentally timed SSRI administration in a genetic mouse model displaying elevated anxiety-like behaviors. METHOD: Knock-in mice containing a common human single-nucleotide polymorphism (Val66Met; rs6265) in brain-derived neurotrophic factor (BDNF), a growth factor implicated in the mechanism of action of SSRIs, were studied based on their established phenotype of increased anxiety-like behavior. Timed administration of fluoxetine was delivered during one of three developmental periods (postnatal days 21-42, 40-61, or 60-81), spanning the transition from childhood to adulthood. Neurochemical and anxiety-like behavioral analyses were performed. RESULTS: We identified a "sensitive period" during periadolescence (postnatal days 21-42) in which developmentally timed fluoxetine administration rescued anxiety-like phenotypes in BDNF Val66Met mice in adulthood. Compared with littermate controls, BDNFMet/Met mice exhibited diminished maturation of serotonergic fibers projecting particularly to the prefrontal cortex, as well as decreased expression of the serotonergic trophic factor S100B in the dorsal raphe. Interestingly, deficient serotonergic innervation, as well as S100B levels, were rescued with fluoxetine administration during periadolescence. CONCLUSIONS: These findings suggest that SSRI administration during a "sensitive period" during periadolescence leads to long-lasting anxiolytic effects in a genetic mouse model of elevated anxiety-like behaviors. These persistent effects highlight the role of BDNF in the maturation of the serotonin system and the capacity to enhance its development through a pharmacological intervention.


Anti-Anxiety Agents/pharmacology , Anti-Anxiety Agents/therapeutic use , Anxiety/drug therapy , Anxiety/genetics , Brain-Derived Neurotrophic Factor/genetics , Fluoxetine/pharmacology , Fluoxetine/therapeutic use , Age Factors , Animals , Dorsal Raphe Nucleus/drug effects , Dorsal Raphe Nucleus/metabolism , Eating/drug effects , Fear/drug effects , Gene Knock-In Techniques , Male , Maze Learning/drug effects , Mice , Polymorphism, Single Nucleotide/genetics , Prefrontal Cortex/drug effects , S100 Calcium Binding Protein beta Subunit/metabolism , Serotonergic Neurons/drug effects , Selective Serotonin Reuptake Inhibitors/pharmacology , Selective Serotonin Reuptake Inhibitors/therapeutic use
3.
Cell Rep ; 7(3): 796-806, 2014 May 08.
Article En | MEDLINE | ID: mdl-24746813

Experience-dependent plasticity shapes postnatal development of neural circuits, but the mechanisms that refine dendritic arbors, remodel spines, and impair synaptic activity are poorly understood. Mature brain-derived neurotrophic factor (BDNF) modulates neuronal morphology and synaptic plasticity, including long-term potentiation (LTP) via TrkB activation. BDNF is initially translated as proBDNF, which binds p75(NTR). In vitro, recombinant proBDNF modulates neuronal structure and alters hippocampal long-term plasticity, but the actions of endogenously expressed proBDNF are unclear. Therefore, we generated a cleavage-resistant probdnf knockin mouse. Our results demonstrate that proBDNF negatively regulates hippocampal dendritic complexity and spine density through p75(NTR). Hippocampal slices from probdnf mice exhibit depressed synaptic transmission, impaired LTP, and enhanced long-term depression (LTD) in area CA1. These results suggest that proBDNF acts in vivo as a biologically active factor that regulates hippocampal structure, synaptic transmission, and plasticity, effects that are distinct from those of mature BDNF.


Brain-Derived Neurotrophic Factor/genetics , Hippocampus/metabolism , Neuronal Plasticity/physiology , Synaptic Transmission/physiology , Alleles , Animals , Brain-Derived Neurotrophic Factor/chemistry , Brain-Derived Neurotrophic Factor/metabolism , Cells, Cultured , Gene Knock-In Techniques , Hippocampus/anatomy & histology , Hippocampus/cytology , Long-Term Synaptic Depression , Mice , Protein Binding , Protein Precursors/genetics , Protein Precursors/metabolism , Receptor, trkB/metabolism , Receptors, Nerve Growth Factor/chemistry , Receptors, Nerve Growth Factor/metabolism , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/metabolism
4.
J Exp Med ; 209(12): 2291-305, 2012 Nov 19.
Article En | MEDLINE | ID: mdl-23091165

Treatment of acute cardiac ischemia focuses on reestablishment of blood flow in coronary arteries. However, impaired microvascular perfusion damages peri-infarct tissue, despite arterial patency. Identification of cytokines that induce microvascular dysfunction would provide new targets to limit microvascular damage. Pro-nerve growth factor (NGF), the precursor of NGF, is a well characterized cytokine in the brain induced by injury. ProNGF activates p75 neurotrophin receptor (p75(NTR)) and sortilin receptors to mediate proapoptotic responses. We describe induction of proNGF by cardiomyocytes, and p75(NTR) in human arterioles after fatal myocardial infarction, but not with unrelated pathologies. After mouse cardiac ischemia-reperfusion (I-R) injury, rapid up-regulation of proNGF by cardiomyocytes and p75(NTR) by microvascular pericytes is observed. To identify proNGF actions, we generated a mouse expressing a mutant Ngf allele with impaired processing of proNGF to mature NGF. The proNGF-expressing mouse exhibits cardiac microvascular endothelial activation, a decrease in pericyte process length, and increased vascular permeability, leading to lethal cardiomyopathy in adulthood. Deletion of p75(NTR) in proNGF-expressing mice rescues the phenotype, confirming the importance of p75(NTR)-expressing pericytes in the development of microvascular injury. Furthermore, deficiency in p75(NTR) limits infarct size after I-R. These studies identify novel, nonneuronal actions for proNGF and suggest that proNGF represents a new target to limit microvascular dysfunction.


Brain/metabolism , Microvessels/pathology , Myocardial Infarction/metabolism , Nerve Growth Factor/metabolism , Pericytes/metabolism , Protein Precursors/metabolism , Reperfusion Injury/metabolism , Animals , Blotting, Western , DNA Primers/genetics , Echocardiography , Enzyme-Linked Immunosorbent Assay , Gene Knock-In Techniques , Humans , Immunohistochemistry , Mice , Microscopy, Electron , Microscopy, Fluorescence , Microvessels/metabolism , Mutagenesis, Site-Directed , Myocardial Infarction/pathology , Nerve Tissue Proteins/deficiency , Nerve Tissue Proteins/metabolism , Receptors, Nerve Growth Factor/deficiency , Receptors, Nerve Growth Factor/metabolism , Reperfusion Injury/pathology
5.
Nat Neurosci ; 12(2): 113-5, 2009 Feb.
Article En | MEDLINE | ID: mdl-19136973

Pro-brain-derived neurotrophic factor (proBDNF) and mature BDNF utilize distinct receptors to mediate divergent neuronal actions. Using new tools to quantitate endogenous BDNF isoforms, we found that mouse neurons secrete both proBDNF and mature BDNF. The highest levels of proBDNF and p75 were observed perinatally and declined, but were still detectable, in adulthood. Thus, BDNF actions are developmentally regulated by secretion of proBDNF or mature BDNF and by local expression of p75 and TrkB.


Brain-Derived Neurotrophic Factor/metabolism , Neurons/metabolism , Protein Precursors/metabolism , Animals , Antibodies, Monoclonal , Brain-Derived Neurotrophic Factor/genetics , Brain-Derived Neurotrophic Factor/immunology , Cell Survival/physiology , Cells, Cultured , Gene Expression Regulation, Developmental , Gene Knock-In Techniques , Hippocampus/cytology , Mice , Mice, Mutant Strains , Neurons/cytology , Protein Precursors/genetics , Protein Precursors/immunology , Receptor, Nerve Growth Factor/metabolism , Receptor, trkB/metabolism
6.
Circ Res ; 102(12): 1558-65, 2008 Jun 20.
Article En | MEDLINE | ID: mdl-18515748

Hyperglycemia is an independent risk factor for development of diabetic vascular complications. The molecular mechanisms that are activated by glucose in vascular cells and could explain the development of vascular complications are still poorly understood. A putative binding site for the transcription factor aryl hydrocarbon receptor (AhR) was identified in the glucose-responsive fragment of the promoter of thrombospondin-1, a potent antiangiogenic and proatherogenic protein involved in development of diabetic vascular complications. AhR was expressed in aortic endothelial cells (ECs), activated, and bound to the promoter in response to high glucose stimulation of ECs. The constitutively active form of AhR induced activation of the thrombospondin-1 gene promoter. In response to high glucose stimulation, AhR was found in complex with Egr-1 and activator protein-2, which are 2 other nuclear transcription factors activated by glucose in ECs that have not been previously detected in complex with AhR. The activity of the DNA-binding complex was regulated by glucose through the activation of hexosamine pathway and intracellular glycosylation. This is the first report of activation of AhR (a receptor for xenobiotic compounds) by a physiological stimulus. This report links the activation of AhR to the pathological effects of hyperglycemia in the vasculature.


Early Growth Response Protein 1/physiology , Endothelial Cells/drug effects , Glucose/pharmacology , Receptors, Aryl Hydrocarbon/drug effects , Thrombospondin 1/genetics , Transcription Factor AP-2/physiology , Animals , Aorta , Cells, Cultured/drug effects , DNA/metabolism , Diabetic Angiopathies/etiology , Endothelial Cells/metabolism , Epithelial Cells/metabolism , Glycosylation , Humans , Hyperglycemia/metabolism , Promoter Regions, Genetic/genetics , Protein Processing, Post-Translational , Rats , Receptors, Aryl Hydrocarbon/physiology , Recombinant Fusion Proteins/biosynthesis , Regulatory Sequences, Nucleic Acid , Thrombospondin 1/biosynthesis , Umbilical Veins
7.
J Biol Chem ; 283(9): 5699-707, 2008 Feb 29.
Article En | MEDLINE | ID: mdl-18096704

Hyperglycemia is an independent risk factor for development of vascular diabetic complications. Vascular dysfunction in diabetics manifests in a tissue-specific manner; macrovasculature is affected by atherosclerotic lesions, and microvascular complications are described as "aberrant angiogenesis": in the same patient angiogenesis is increased in some tissues (e.g. retinal neovascularization) and decreased in others (e.g. in skin). Molecular cell- and tissue-specific mechanisms regulating the response of vasculature to hyperglycemia remain unclear. Thrombospondin-1 (TSP-1), a potent antiangiogenic and proatherogenic protein, has been implicated in the development of several vascular diabetic complications (atherosclerosis, nephropathy, and cardiomyopathy). This study examines cell type-specific regulation of production of thrombospondin-1 by high glucose. We previously reported the increased expression of TSP-1 in the large arteries of diabetic animals. mRNA and protein levels were up-regulated in response to high glucose. Unlike in macrovascular cells, TSP-1 protein levels are dramatically decreased in response to high glucose in microvascular endothelial cells and retinal pigment epithelial cells (RPE). This down-regulation is post-transcriptional; mRNA levels are increased. In situ mRNA hybridization and immunohistochemistry revealed that the level of mRNA is up-regulated in RPE of diabetic rats, whereas the protein level is decreased. This cell type-specific posttranscriptional suppression of TSP-1 production in response to high glucose in microvascular endothelial cells and RPE is controlled by untranslated regions of TSP-1 mRNA that regulate coupling of TSP-1 mRNA to polysomes and its translation. The cell-specific regulation of TSP-1 suggests a potential mechanism for the aberrant angiogenesis in diabetics and TSP-1 involvement in development of various vascular diabetic complications.


Angiogenesis Inhibitors/biosynthesis , Atherosclerosis/metabolism , Diabetes Complications/metabolism , Glucose/pharmacology , Hyperglycemia/metabolism , Neovascularization, Pathologic/metabolism , Sweetening Agents/pharmacology , Thrombospondin 1/biosynthesis , Animals , Atherosclerosis/etiology , Atherosclerosis/pathology , Cattle , Cells, Cultured , Diabetes Complications/pathology , Down-Regulation/drug effects , Endothelial Cells/metabolism , Endothelial Cells/pathology , Humans , Hyperglycemia/complications , Hyperglycemia/pathology , In Situ Hybridization , Neovascularization, Pathologic/etiology , Organ Specificity/drug effects , Pigment Epithelium of Eye/metabolism , Pigment Epithelium of Eye/pathology , Protein Biosynthesis/drug effects , Rats , Rats, Zucker
8.
J Biol Chem ; 282(8): 5704-14, 2007 Feb 23.
Article En | MEDLINE | ID: mdl-17178709

Accelerated development of atherosclerotic lesions remains the most frequent and dangerous complication of diabetes, accounting for 80% of deaths among diabetics. However, our understanding of the pathways mediating glucose-induced gene expression in vascular cells remains controversial and incomplete. We have identified an intracellular metabolic pathway activated by high glucose in human aortic smooth muscle cells that mediates up-regulation of thrombospondin-1 (TSP-1). TSP-1 is a potent antiangiogenic and proatherogenic protein that may represent an important link between diabetes and vascular complications. Using different glucose analogs and metabolites sharing distinct, limited metabolic steps with glucose, we demonstrated that activation of TSP-1 transcription is mediated by the hexosamine pathway of glucose catabolism, possibly resulting in modulation of the activity of nuclear proteins activity through their glycosylation. Specific inhibitors of glutamine: fructose 6-phosphate amidotransferase (GFAT), an enzyme controlling the hexosamine pathway, as well as direct inhibitors of protein glycosylation efficiently inhibited TSP-1 transcription and the activity of a TSP-1 promoter-reporter construct stimulated by high glucose. Overexpression of recombinant GFAT resulted in increased TSP-1 levels. Pharmacological inhibition of GFAT or protein glycosylation inhibited increased proliferation of human aortic smooth muscle cells caused by glucose. We have demonstrated that the hexosamine metabolic pathway mediates up-regulation of TSP-1 by high glucose. Our results suggest that the hexosamine pathway and intracellular glycosylation may control important steps in initiation and development of atherosclerotic lesions.


Angiogenesis Inhibitors/biosynthesis , Atherosclerosis/metabolism , Muscle, Smooth, Vascular/metabolism , Myocytes, Smooth Muscle/metabolism , Thrombospondin 1/biosynthesis , Up-Regulation , Angiogenesis Inhibitors/genetics , Aorta/metabolism , Aorta/pathology , Atherosclerosis/genetics , Atherosclerosis/pathology , Cells, Cultured , Glucose/pharmacology , Glutamine-Fructose-6-Phosphate Transaminase (Isomerizing)/genetics , Glutamine-Fructose-6-Phosphate Transaminase (Isomerizing)/metabolism , Glycosylation/drug effects , Muscle, Smooth, Vascular/pathology , Myocytes, Smooth Muscle/pathology , Sweetening Agents/pharmacology , Thrombospondin 1/genetics , Up-Regulation/drug effects
9.
FASEB J ; 19(13): 1893-5, 2005 Nov.
Article En | MEDLINE | ID: mdl-16148025

Recent genetic studies have associated members of the thrombospondin (TSP) gene family with premature cardiovascular disease. The disease-associated polymorphisms lead to single amino acid changes in TSP-4 (A387P) and TSP-1 (N700S). These substitutions reside in adjacent domains of these highly homologous proteins. Secondary structural predictive programs and the homology of the domains harboring these amino acid substitutions to those in other proteins pointed to potential alterations of putative Ca2+ binding sites that reside in close proximity to the polymorphic amino acids. Since Ca2+ binding is critical for the structure and function of TSP family members, direct evidence for differences in Ca2+ binding by the polymorphic forms was sought. Using synthetic peptides and purified recombinant variant fragments bearing the amino acid substitutions, we measured differences in Tb3+ luminescence as an index of Ca2+ binding. The Tb3+ binding constants placed the TSP-1 region affected by N700S polymorphism among other high-affinity Ca2+ binding sites. The affinity of Ca2+ binding was lower for peptides (3.5-fold) and recombinant fragments (10-fold) containing the S700 vs. the N700 form. In TSP-4, the P387 form acquired an additional Ca2+ binding site absent in the A387 form. The results of our study suggest that both substitutions (A387P in TSP-4 and N700S in TSP-1) alter Ca2+ binding properties. Since these substitutions exert the opposite effects on Ca2+ binding, a decrease in TSP-1 and an increase in TSP-4, the two TSP variants are likely to influence cardiovascular functions in distinct but yet pathogenic ways.


Calcium/chemistry , Polymorphism, Genetic , Thrombospondin 1/genetics , Thrombospondins/genetics , Amino Acid Sequence , Amino Acids/chemistry , Binding Sites , Calmodulin/chemistry , Cardiovascular System/pathology , Dose-Response Relationship, Drug , Genetic Variation , Humans , Integrins/chemistry , Ions , Kinetics , Models, Molecular , Molecular Sequence Data , Mutation , Peptides/chemistry , Polymorphism, Single Nucleotide , Protein Binding , Protein Structure, Secondary , Protein Structure, Tertiary , Recombinant Proteins/chemistry , Reverse Transcriptase Polymerase Chain Reaction , Sequence Homology, Amino Acid , Spectrophotometry , Terbium/chemistry , Tryptophan/chemistry , Ultraviolet Rays
...